Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Entereg
Alvimopan is a peripherally acting mu-opioid receptor antagonist specifically developed to counteract the adverse effects of opioids on bowel function, particularly postoperative ileus (POI), without affecting opioid-mediated analgesia within the central nervous system. It belongs to a class of drugs known as opioid antagonists and works primarily in the gastrointestinal tract.
For the prevention of postoperative ileus following bowel resection surgery.
Increased risk of myocardial infarction with long-term use.
Outcome:
Significantly decreases alvimopan levels
Mechanism:
Potent CYP3A4 inducer
Outcome:
Increased alvimopan plasma concentrations
Mechanism:
Reduced metabolism of alvimopan
Outcome:
Potential decreased efficacy of alvimopan in reversing opioid-induced bowel dysfunction
Mechanism:
Competitive binding at mu-opioid receptors
Most likely new formulation: extended-release oral dosage form (2026, 60% confidence)
Based on current usage trends and post-market surveillance data, there is a low (<5%) likelihood of significant regulatory changes in the near future.
Opioid antagonist
Morphinan derivative